Skip to content
All Sections
Subscribe Now
78°F
Monday, August 26th 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
78°F
Monday, August 26th 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Michelin-starred chef's new restaurant
121st Naples Island Swim ð
Homeless man fatally shot
High School Football
No contest plea in fatal shooting
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Coya Therapeutics, Inc.
< Previous
1
2
Next >
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024
August 19, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
August 12, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
August 02, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
July 31, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
June 20, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
June 11, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
June 03, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
May 28, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
May 22, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
May 20, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
May 09, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
April 26, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
April 22, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
April 18, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
April 08, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
March 19, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics to Participate in BTIG Fireside Discussion
March 12, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
March 12, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
March 06, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
February 29, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
February 22, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
February 21, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
February 13, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
January 29, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
January 18, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
January 16, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
January 05, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
December 20, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
December 13, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
December 12, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close